Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma
暂无分享,去创建一个
[1] M. Tsao,et al. KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] S. Moon,et al. Effective method for the isolation and proliferation of primary lung cancer cells from patient lung tissues , 2013, Biotechnology Letters.
[3] M. Spitz,et al. Role of Selected Genetic Variants in Lung Cancer Risk in African Americans , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] T. Stinchcombe,et al. KRAS mutation: should we test for it, and does it matter? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] B. Parasuraman,et al. EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital , 2013, PloS one.
[6] Y. Yatabe,et al. Surgery for NSCLC in the era of personalized medicine , 2013, Nature Reviews Clinical Oncology.
[7] Mishal N. Patel,et al. Objective assessment of cancer genes for drug discovery , 2012, Nature Reviews Drug Discovery.
[8] L. Ma,et al. Meta-analysis demonstrates lack of association of the hOGG1 Ser326Cys polymorphism with bladder cancer risk. , 2012, Genetics and molecular research : GMR.
[9] Li Ding,et al. Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.
[10] A. Powers,et al. Comparative Effectiveness of Dalteparin and Enoxaparin in a Hospital Setting , 2012, Journal of pharmacy practice.
[11] D. Kerr,et al. Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.
[12] R. Motzer,et al. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.
[13] Y. Bang,et al. Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes , 2011, Cellular Oncology.
[14] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[15] William Pao,et al. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.
[16] H. Ji,et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Y. Nakanishi,et al. Lung Cancer Risk and Genetic Polymorphisms in DNA Repair Pathways: A Meta-Analysis , 2010, Journal of nucleic acids.
[18] Luc Girard,et al. Lung cancer cell lines as tools for biomedical discovery and research. , 2010, Journal of the National Cancer Institute.
[19] L. Benesova,et al. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. , 2010, Anticancer research.
[20] T. Mitsudomi,et al. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation , 2010, Cancer and Metastasis Reviews.
[21] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[22] Juan Yang,et al. Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients , 2010, Acta Pharmacologica Sinica.
[23] Varda Rotter,et al. When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.
[24] M Eileen Dolan,et al. Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy , 2009, Clinical Cancer Research.
[25] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[26] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[27] R. Hruban,et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.
[28] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[29] C. Eaves,et al. Enzymatic dissociation and culture of normal human mammary tissue to detect progenitor activity. , 2005, Methods in molecular biology.
[30] M. Feldman,et al. Genetic Structure of Human Populations , 2002, Science.
[31] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[32] Thierry Soussi,et al. Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.
[33] A. Levine,et al. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.
[34] J. Minna,et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] J. Minna,et al. Comparison of features of human breast cancer cell lines and their corresponding tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] P. Sutphin,et al. The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent , 1998, Molecular and Cellular Biology.
[37] L. Neckers,et al. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] T. Aas,et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.
[39] J. Momand,et al. Heat Shock Protein 84 Forms a Complex with Mutant p53 Protein Predominantly within a Cytoplasmic Compartment of the Cell* , 1996, The Journal of Biological Chemistry.
[40] A. Gazdar,et al. Cell culture methods for the establishment of the NCI series of lung cancer cell lines , 1996, Journal of cellular biochemistry. Supplement.
[41] L. Holmberg,et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.
[42] R. Link,et al. Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. , 1989, The Journal of investigative dermatology.
[43] A. Levine,et al. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines , 1987, Molecular and cellular biology.
[44] J. Minna,et al. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. , 1986, Cancer research.